Noncoding RNA in drug resistant sarcoma by Li, Xiaoyang et al.
Noncoding RNA in drug resistant sarcoma
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Li, Xiaoyang, Jacson K. Shen, Francis J. Hornicek, Tao Xiao, and
Zhenfeng Duan. 2017. “Noncoding RNA in drug resistant sarcoma.”
Oncotarget 8 (40): 69086-69104. doi:10.18632/oncotarget.19029.
http://dx.doi.org/10.18632/oncotarget.19029.
Published Version doi:10.18632/oncotarget.19029
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:34492246
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
Oncotarget69086www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/              Oncotarget, 2017, Vol. 8, (No. 40), pp: 69086-69104
Noncoding RNA in drug resistant sarcoma
Xiaoyang Li1,2, Jacson K. Shen2, Francis J. Hornicek2, Tao Xiao1 and Zhenfeng Duan2
1Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China
2Sarcoma Biology Laboratory, Department of Orthopaedic Surgery, Massachusetts General Hospital and Harvard Medical 
School, Boston, Massachusetts, 02114, USA
Correspondence to: Tao Xiao, email: xiaotaoxyl@163.com 
Zhenfeng Duan, email: zduan@mgh.harvard.edu
Keywords: noncoding RNA (ncRNA), microRNA (miR), long noncoding RNA (lncRNA), drug resistance, sarcoma
Received: May 04, 2017    Accepted: June 26, 2017    Published: July 06, 2017
Copyright: Li et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
ABSTRACT
Sarcomas are a group of malignant tumors that arise from mesenchymal origin. 
Despite significant development of multidisciplinary treatments for sarcoma, survival 
rates have reached a plateau. Chemotherapy has been extensively used for sarcoma 
treatment; however, the development of drug resistance is a major obstacle limiting 
the success of many anticancer agents. Sarcoma biology has traditionally focused 
on genomic and epigenomic deregulation of protein-coding genes to identify the 
therapeutic potential for reversing drug resistance. New and more creative approaches 
have found the involvement of noncoding RNAs, including microRNAs and long 
noncoding RNAs in drug resistant sarcoma. In this review, we discuss the current 
knowledge of noncoding RNAs characteristics and the regulated genes involved in 
drug resistant sarcoma, and focus on their therapeutic potential in the future.
INTRODUCTION
Sarcomas are a group of heterogeneous malignant 
tumors that arise from mesenchymal origin. These 
malignancies are characterized by more than 50 subtypes 
with distinct clinical presentation and histology [1]. 
Although relatively rare, sarcomas account for nearly 
21% of all pediatric solid cancers and are the third 
leading cause of cancer-related deaths in patients under 
the age of 20 [2, 3]. Despite the significant development 
of novel multidisciplinary treatments, including surgery, 
chemotherapy and radiation therapy, the 5-year survival 
rate has reached to a plateau in recent years [4]. This 
phenomenon is seen particularly in patients with metastatic 
or recurrent advanced disease, where the overall median 
survival is around 15 months, and only about 10% of these 
cases are still alive at five years [5]. 
Since the introduction of adjuvant and neoadjuvant 
chemotherapy in the 1970s, chemotherapy with 
multimodality therapeutic strategies have made 
considerable progress in improving the survival rate 
and quality of life for patients with certain types of 
sarcomas, especially for osteosarcoma, Ewing’s sarcoma 
and rhabdomyosarcoma [6–12]. However, progress 
has remained stagnant over the last three decades with 
conventional chemotherapy approach [13, 14]. The 
development of drug resistance to chemotherapy is 
one of the major reasons for treatment failure, but the 
mechanisms of drug resistance have not been completely 
understood. Multiple subtypes make drug resistance 
mechanisms more diverse and controversial in sarcoma. 
To date, none of the ongoing attempts to address current 
mechanisms have been applied in the clinic with the 
aim of restoring drug efficacy in sarcoma. Therefore, 
identification of novel mechanisms of drug resistance in 
sarcoma that can be directly translated to clinic is required.
With the rapid development of next-generation 
sequencing technology to whole genomes and 
transcriptomes, it has been shown that only 2% of the human 
genome encodes mRNAs, whereas 98% of transcriptional 
products are noncoding RNAs (ncRNAs) [15]. ncRNAs 
have emerged as a class of cellular regulators involved in 
biological processes such as proliferation, differentiation, 
apoptosis and cell cycle, whereas mutations and 
dysregulation of ncRNAs have been linked to diverse human 
diseases, including sarcomas [16, 17]. Recent evidence 
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has highlighted ncRNAs as being associated with drug 
resistance in sarcoma, mainly in two distinct subtype forms: 
microRNAs (miRs) and long noncoding RNAs (lncRNAs). 
miRs have moved to the forefront of ncRNA research in the 
past decade, while the role of lncRNAs is also emerging in 
different areas of cancer biology [18]. In this review, we 
summarize recent discoveries of the molecular functions of 
ncRNAs in cellular pathways related to drug resistance, and 
their potential as novel therapeutic strategies to overcome 
treatment failure of chemotherapies in sarcoma.
NCRNAS AND DRUG RESISTANCE IN 
SARCOMA
ncRNAs are extensively transcribed within the 
human genome [19, 20]. They lack valid open reading 
frames and have no protein-coding capacity [21–23]; 
however, ncRNAs represent a broad class of structurally 
and functionally distinct RNAs (Table 1). These include 
long and short ncRNAs that represent around 60% of the 
RNAs distributed throughout the human genome [24, 25]. 
Short ncRNAs are no more than 200 nucleotides (nt) 
[26]. This group is composed of miR, PIWI interacting 
RNA, small nucleolar RNA, and others [26]. In contrast, 
transcripts longer than 200 nt are regarded as lncRNAs 
[27]. This group is diverse and highly abundant [28], and 
contains long intergenic ncRNAs, long intronic ncRNAs, 
pseudogene RNAs, to name a few [26]. Novel classes 
of ncRNAs are constantly being discovered, including 
circular RNAs [29] and enhancer RNAs [30]. 
ncRNAs were considered to be junk or debris 
derived from the DNA transcriptional process initially [25]. 
However, recent studies have revealed that ncRNAs could 
be deregulated or mutated in many human cancers and they 
play an important role in pathological processes, including 
in tumorigenesis, metastasis and treatment resistance 
[31–34]. The development of drug resistance in sarcoma is 
affected by many factors, most of which involve a change 
in expression of certain genes. Mutations, amplifications 
or deletions within oncogenes and/or tumor suppressors 
were considered to be associated with the development 
of drug resistance [35–37]. ncRNAs have emerged as 
major regulators of epigenetic, transcriptional, and post-
transcriptional gene expression and alternative splicing, 
which provides cells with yet another mode to fine-tune 
their transcriptome and adjust their proteome in response to 
stimuli. ncRNAs, mainly in the form of miRs and lncRNAs, 
have been linked to sarcoma drug resistance through 
abnormal gene regulation related to the activity of drug 
efflux transporters; the activation of drug target mutations 
or changes; DNA repair and cell cycle arrest; apoptosis 
and cell-survival pathways; cancer stem cells (CSCs) and 
autophagy involved signaling pathways [38–42]. 
ROLE OF MIRS IN DRUG RESISTANT 
SARCOMA
miRs are a large family of conserved endogenous 
single-stranded small ncRNAs derived from the human 
genome [43]. The initial discovery of miR was in 1993 
[44], and to date, over 1,400 human miRs have been 
identified [45]. Over one-third of the genes in human 
genome are regulated by miRs [46]. miRs bind to the 
3ʹ-untranslated region (3ʹ-UTR) of its mRNA target, 
based on a partial base-pairing complementarity [47]. 
Translation of the mRNA is ultimately prevented either by 
transcript degradation, inhibition of translation, or mRNA 
decay, leading to a reduced level of protein [48]. 
Mutation patterns or aberrant expressions of miRs 
have been detected in sarcoma and have been associated 
with clinical features such as progression, metastasis 
and drug resistance [49]. Upregulation of miRs induces 
variations in drug metabolism and disposition through 
the regulation of target mRNAs (Table 2). The products 
of these target genes can be drug transporters, nuclear 
receptors, transcription factors or drug-metabolizing 
enzymes [50]. This leads to altered expression of proteins 
that are involved in the signal transduction network of drug 
resistance, and ultimately changing the chemosensitivity 
of cancer cells [51].
miRs are associated with changes to drug targets 
in drug resistant sarcoma
 Quantitative or qualitative alterations to drug 
targets can be a factor contributing to drug resistance. 
miRs that inhibit DNA topoisomerase 2A (Top2A), 
such as miR-143, are implicated in drug resistance 
in dedifferentiated liposarcoma (Figure 1). The miR 
expression profile showed a decreased miR-143 in 
dedifferentiated liposarcoma tissues. Restored miR-
143 decreased the expression of Top2A, inhibited 
proliferation and induced apoptosis in dedifferentiated 
liposarcoma cells. Top2A encoded by the Top2A gene is 
a nuclear enzyme. It catalyzes the transient breaking and 
rejoining of two strands of duplex DNA, thus altering 
the topology of DNA for transcription and replication 
[52]. The gene encoding Top2A functions as the target 
for several chemotherapeutic agents used for sarcoma 
treatment, such as doxorubicin (DOX) and etoposide 
[53]. Amplification or mutations in this gene have been 
associated with the development of drug resistance. In 
dedifferentiated liposarcoma, reduced expression of 
miR-143 increased nuclear expression of Top2A and 
cell proliferation, and this led to the dedifferentiated 
liposarcoma cells acquiring resistance to Top2A-targeted 
drugs [54]. 
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miRs influence DNA repair in drug resistant 
sarcoma
miRs that have an impact on DNA repair, such as 
miR-124 and miR-708, are implicated in resistance to 
drugs aimed at damage tumor cell DNA (Figure 1). The 
damaged DNA leads to genetic instability and in turn 
activates apoptosis, when DNA repair proves inefficient. 
Overexpression of miR-124 reduced poly ADP-ribose 
polymerase 1 (PARP1) and ataxia telangiectasia mutated 
interactor (ATMIN) proteins expression in osteosarcoma 
cells, which reduced DNA repair capacity and increased 
sensitivity to DNA-damaging drugs, such as DOX [55]. 
Overexpression of miR-124 induced the DNA repair 
defect through binding to the 3ʹ-UTR of the mRNAs of 
PARP1 and ATMIN, thus reversed drug resistance in 
Table 1: Classes of discovered human ncRNAs
Noncoding 
RNAs
Class Symbol Length (nt) Functions Significance
House-
keeping 
ncRNAs
Transfer RNAs tRNAs 73–94 Connect amino acids with mRNA Translation
Ribosomal RNAs rRNAs 121–5070 Component of ribosome Translation
Vault RNAs vRNAs 86–141 Component of vault Expulsion of xenobiotics, such as 
chemotherapeutic compounds
Small 
ncRNAs
MicroRNAs miRNAs 18–25 Modulate protein-coding genes, guide 
suppression of translation, Drosha and 
Dicer dependent small ncRNAs
Regulation of proliferation,
differentiation, and apoptosis involved in 
human development
Piwi-interacting 
RNAs
piRNAs 26–30 Bind to Piwi proteins, principally 
restricted to the germline
Involved in germ cell development, stem 
self-renewal, and retrotransposon silencing
Small nuclear 
RNAs
snRNAs 150~ Assemble with proteins into 
spliceosomes to remove introns during 
mRNA processing
Aid in the regulation of transcription 
factors or RNA polymerase II, maintaining 
the telomeres
Small nucleolar 
RNAs
snoRNAs 60–200 Guide modifications of other noncoding 
RNAs, function as miRNA to regulate 
mRNAs, alternative splicing
Associated with the development of some 
cancers
Promoter-associated 
small RNAs
paRNAs 20–200 Involved in the regulation of the 
transcription of protein-coding genes 
by targeting epigenetic silencing 
complexes
Relation to diseases has not yet been 
discovered
Transcription 
initiation RNAs
tiRNAs ~18 Involved in the regulation of the 
transcription of protein-coding genes 
by targeting epigenetic silencing 
complexes
Relation to diseases has not yet been 
discovered
Long 
ncRNAs
Long intergenic 
noncoding RNAs
lincRNAs > 200 Involved in diverse biological 
processes, such as mRNA splicing and 
miRNA silencing
Involved in tumorigenesis and cancer 
metastasis
Long intronic 
noncoding RNAs
> 200 Likely to be involved in post-
transcriptional gene silencing
Aberrantly expressed in human cancers
Telomere associated 
noncoding RNAs
TERRAs > 200 Negative regulation of
telomere length and activity through 
inhibition of telomerase
Possible impact on telomere-associated 
diseases, including many cancers
Long noncoding 
RNAs with dual 
functions
> 200 Both protein-coding and functionally 
regulatory RNA capacity
Deregulation has been described in cancers
Transcribed 
pseudogenes
> 200 Regulation of tumor suppressors and 
oncogenes by acting as microRNA 
decoys
Often deregulated during tumorigenesis 
and cancer progression
Transcribed-
ultraconserved 
regions
T-UCRs > 200 Antisense inhibitors for protein-coding 
genes or other ncRNAs
Expression is often altered in some 
cancers, possible involvement in 
tumorigenesis
Circular RNAs circRNAs > 100 Do not have 5ʹ or 3ʹ ends, act as miRNA 
sponge, transport miRNAs, regulate 
mRNA through limited base pairing
May be used to study pathogenesis and 
devise therapeutic interventions
Enhancer RNAs eRNAs 50–2000 Important components in enhancer 
activity, have effect on the trans-
criptional regulation in cis and in trans
May provide promising regulatory routes 
in tumor suppression
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osteosarcoma [55]. Decreased expression of another 
miR, miR-708, induced EYA3 expression and led to drug 
resistance in Ewing’s sarcoma. EYA3 is a highly expressed 
transcriptional cofactor that enhances DNA repair in 
response to DNA damage. Restored miR-708 directly 
targeted EYA3 and reduced its expression, thus sensitized 
Ewing’s sarcoma cells to the DNA-damaging drugs 
etoposide and DOX. This confirmed that miR-708 could 
be a promising target for sensitization to DNA-damaging 
drugs applied in the treatment of Ewing’s sarcoma [56]. 
miRs regulate cell cycle-associated genes in drug 
resistant sarcoma
miRs associated with drug resistance have been 
shown to regulate genes related to cell cycle in sarcoma, 
include miR-17, miR-140, miR-215 and miR-143 
(Figure 1). Overexpression of miR-17 suppressed DOX-
evoked higher expression of p21, a tumor suppressor, 
and conferred the drug resistance in synovial sarcoma. 
Treatment of the synovial sarcoma cells with anti-miR-17 
rescued expression of p21, which may be a therapeutic 
target to reverse drug resistance in sarcoma [57]. miR-
140 is involved in chemosensitivity with reduced cell 
proliferation via G1 and G2 phase arrest mediated in part, 
by the suppression of histone deacetylase 4 (HDAC4) 
expression. HDAC4 is related to chemoresistance via 
repression of p21 and regulating cell-cycle progression 
and differentiation. Transfection with miR-140 reversed 
methotrexate-resistance through induction of the p21 
gene accompanied by G1 and G2 phase arrest only in cell 
lines containing wild type of p53 [58]. Another miR, miR-
215, inhibited expression of denticleless protein homolog 
(DTL) and led to an increased resistance to methotrexate 
and Tomudex in osteosarcoma. DTL is a cell cycle 
G2/M checkpoint regulatory protein. Inhibition of DTL 
induced G2-arrest and decreased cell proliferation. miR-
215 inhibited expression of the DTL gene accompanied 
by upregulation of p21 resulting in G2-arrest, and thus 
drug resistance emerged in osteosarcoma [59]. Protein 
Regulator of cytokinesis 1 (PRC1) is a protein that is 
highly expressed during S and G2/M phases of the cell 
cycle [60]. Polo-like kinase 1 (PLK1) or serine/threonine-
protein kinase 13 (STPK13), is an early trigger enzyme 
Figure 1: miRs involved in drug target alterations, DNA repair and cell cycle in drug resistant sarcoma. miRs that 
regulate gene expression of crucial proteins in drug targets, DNA repair and cell cycle are implicated in drug resistance in sarcoma. Red 
arrows indicate upregulation of miRs and green arrows indicate downregulation. 
Oncotarget69090www.impactjournals.com/oncotarget
Table 2: Summary of miRs involved in drug resistant sarcoma
miRs Sarcomas Alteration Drugs Resistance 
mechanisms
Major targets References
miR-143 Liposarcoma 
Osteosarcoma
↓ Doxorubicin Alterations in drug 
targets
Cell cycle
Evasion of apoptosis
Cancer stem cells
Autophagy
Top2A
PRC1
PLK1
Bcl-2 
ALDH1
CD133 
ATG2B
LC3-II
[54, 103]
miR-124 Osteosarcoma ↓ Camptothecin
Etoposide
Doxorubicin
DNA repair ATMIN
PARP1
[55]
miR-708 Ewing’s sarcoma ↓ Doxorubicin 
Etoposide
DNA repair EYA3 [56]
miR-17 Synovial 
sarcoma
↑ Doxorubicin Cell cycle p21 [57]
miR-140 Osteosarcoma ↓ Methotrexate Cell cycle HDAC4 [58]
miRNA-215 Osteosarcoma ↑ Methotrexate Cell cycle DTL [59]
miR-301a Osteosarcoma ↑ Doxorubicin Evasion of apoptosis AMPKα1 [63]
miR-382 Osteosarcoma ↓ Doxorubicin
Cisplatin
Methotrexate
Evasion of apoptosis HIPK3 [64]
Let-7d Osteosarcoma ↑ Doxorubicin
Cisplatin
Paclitaxel
Etoposide
Evasion of apoptosis
Cancer stem cells
Bcl-2
Caspase-3 
Oct3/4
Sox2
Nanog
Lin28B
HMGA2
[65]
miR-138 Osteosarcoma ↓ Cisplatin Evasion of apoptosis EZH2 [66]
miR-21 Osteosarcoma ↑ Cisplatin Evasion of apoptosis Bcl-2 [67, 68]
miR-34a Ewing’s sarcoma ↓ Doxorubicin
Vincristine
Evasion of apoptosis Not reported [69]
miR-125b Ewing’s sarcoma ↑ Doxorubicin
Etoposide
Vincristine
Evasion of apoptosis P53
Bak
[74]
miRNA-193a-
5p
Osteosarcoma 
Ewing’s sarcoma
↑ Cisplatin Evasion of apoptosis
Activation of cell-
survival pathways
TAp73β
Wnt/β-catenin 
pathway
[75, 90]
miR-202 Osteosarcoma ↑ Doxorubicin Activation of cell-
survival pathways
PDCD4 [76]
miR-221 Osteosarcoma ↑ Cisplatin Activation of cell-
survival pathways
PTEN [82]
miR-217 Osteosarcoma ↓ Cisplatin Activation of cell-
survival pathways
KRAS [86]
miR-100 Chondrosarcoma ↓ Cisplatin Activation of cell-
survival pathways
mTOR [87]
miR-497 Osteosarcoma ↓ Cisplatin Activation of cell-
survival pathways
VEGFA [89]
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for G2/M transition [61]. miR-143 was downregulated 
in dedifferentiated liposarcoma. Restoring miR-143 
expression inhibited cytokinesis in dedifferentiated 
liposarcoma cells, with decreased expression of PRC1 and 
PLK1. Treatment with a PLK1 inhibitor potently induced 
G2-M cell cycle arrest and apoptosis in liposarcoma cells, 
indicating that miR-143 could be a therapeutic target for 
the reversal of drug resistance [54].
miRs affect evasion of apoptosis in drug resistant 
sarcoma
Dysfunctions of miRs, including miR-301a, 
miR-382, Led-7, miR-21, miR-34a and miR-125b, 
are associated with defective apoptosis-induced drug 
resistance in sarcoma (Figure 2) [62]. DOX treatment 
promoted the cleavage of caspase-3, which was blocked 
by miR-301a in osteosarcoma, suggesting that miR-301a 
enhanced the resistance of osteosarcoma cells to DOX by 
inhibiting apoptosis [63]. miR-382, increased cleavage 
of caspase-3 and enhanced drug-induced cell apoptosis 
in osteosarcoma. Downregulation of miR-382 was 
associated with a poor chemoresponse to DOX, cisplatin 
(CDDP), and methotrexate in osteosarcoma [64]. High 
expression of Let-7d also decreased caspase-3 cleavage 
induced by chemotherapeutic agents, in combination with 
reduced apoptosis and drug resistance in osteosarcoma 
[65]. In contrast, increased miR-138 expression enhanced 
caspase-3 activation and CCDP-induced apoptosis by 
targeting EZH2, resulting in reinforcing chemosensitivity 
to CCDP in osteosarcoma [66]. 
miR-21 is implicated in the modulation of drug 
resistance in sarcoma and serum miR-21 can serve as a 
potential biomarker for prediction of chemotherapeutic 
sensitivity in patients with osteosarcoma [67]. 
Transfection with miR-21 mimics depleted the sensitivity 
miR-92a
miR-99b
miR-422a
Osteosarcoma ↑ Ifosfamide Wnt/β-catenin 
pathway
[90]
miR-132 Osteosarcoma ↓ Ifosfamide Activation of cell-
survival pathways
Wnt/β-catenin 
pathway
[90]
miR-33a Osteosarcoma ↑ Cisplatin Activation of cell-
survival pathways
TWIST [91]
miR-34c Osteosarcoma ↓ Doxorubicin
Cisplatin
Methotrexate
Activation of cell-
survival pathways
North1
LEF1
[93]
miR-146b-5p Osteosarcoma ↑ Doxorubicin
Cisplatin
Methotrexate
Activation of cell-
survival pathways
ZNRF3 [97]
miR-199a-3p Osteosarcoma ↓ Doxorubicin Cancer stem cells CD44 [102]
miR-29b-1 Osteosarcoma ↓ Doxorubicin
Cisplatin
Etoposide
Cancer stem cells Oct3/4
Sox2
Nanog
CD133
N-Myc
CCND2
[105]
miR-199-5p Osteosarcoma ↓ Cisplatin Autophagy LC3-II
Beclin-1
[114]
miR-30a Osteosarcoma ↓ Doxorubicin Autophagy Beclin-1 [115]
miR-22 Osteosarcoma ↑ Doxorubicin
Cisplatin
Autophagy HMGB1 [117, 118]
miR-101 Osteosarcoma ↓ Doxorubicin Autophagy LC3
AVOs
[119]
miR-488 Osteosarcoma ↑ Doxorubicin Evasion of apoptosis Bim [145]
miR-184 Osteosarcoma ↑ Doxorubicin Evasion of apoptosis Bcl-2 [146]
miR-23b Chondrosarcoma ↓ Cisplatin Evasion of apoptosis Src-Akt 
pathway
[149]
miR-141 Neuroblastoma ↓ Cisplatin Not reported FUS gene [150]
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of osteosarcoma cells to CDDP, while miR-21 suppression 
led to enhanced CDDP cytotoxicity. Changes in 
chemoresponse induced by miR-21 upregulation were 
ameliorated by downregulation of apoptotic inhibitor 
Bcl-2 [68]. In addition to miR-21, miR Let-7d also 
reduced cell sensitivity to DOX, CDDP, etoposide and 
paclitaxel, consistent with increased expression of Bcl-2 
in osteosarcoma [65]. 
miR-34a was associated with good prognosis in 
Ewing’s sarcoma, and reinforced that miR-34a could 
sensitize Ewing’s sarcoma cells to DOX and vincristine 
[69]. miR-34a is a component of the p53 tumor suppressor 
network [70]. Loss of miR-34a is mainly caused by 
inactivating mutations of p53, genetic alterations of the 
region Chr1p36 (which contains the coding region for 
miR-34a), or epigenetic changes [71–73]. miR-125b 
could induce drug resistance through evasion of p53-
dependent apoptosis in DOX-resistant Ewing’s sarcoma 
cells. Knockdown of miR-125b enhanced the sensitivity 
of Ewing’s sarcoma cells to DOX, which was associated 
with an increased level of p53. In addition to DOX, 
overexpression of miR-125b also resulted in enhanced 
resistance to etoposide and vincristine in Ewing’s sarcoma 
[74]. Other members of the p53 tumor suppressor network 
also influence drug-induced apoptosis in sarcoma. High 
levels of miR-193a-5p blocked CDDP-induced apoptosis 
via inhibition of TAp73β, a p53-family protein. The role 
of the miR-193a-5p/TAp73β axis in drug resistance was 
confirmed in sarcomas, including in osteosarcoma and 
Ewing’s sarcoma [75].
miRs interfere with cell-survival pathways in 
drug resistant sarcoma
Expressions of miRs interfere with cell growth and 
survival mediated by the PI3K/Akt pathway, which plays 
a role in drug resistance in sarcoma (Figure 3). To identify 
PI3K/Akt-related miRs, a group of miRs was shown to have 
elevated expression upon treatment of drugs, such as miR-
202 and miR-221, while other miRs were downregulated, 
including miR-217, miR-100 and miR-497. Overexpression 
of miR-202 promoted drug resistance by targeting 
programmed cell death 4 (PDCD4) in osteosarcoma [76]. 
PDCD4 is a tumor suppressor that inhibits the PI3K/
Akt pathway and enhances apoptosis [77]. Activation 
of the PI3K/Akt pathway leads to drug resistance, while 
suppression of PI3K/Akt signaling in turn restores drug 
sensitivity in cancers, including in sarcoma [78–81]. High 
levels of miR-221 in osteosarcoma also induced resistance 
to CDDP and increased cell survival by suppressing PTEN 
Figure 2: ncRNAs associated with apoptosis and drug efflux in drug resistant sarcoma. miRs and lncRNAs that interfere 
with gene expression of significant proteins in apoptosis and drug efflux have an impact on drug resistance in sarcoma. Red arrows indicate 
upregulation of miRs and green arrows indicate downregulation.
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expression [82]. miR-221 directly targeted the 3ʹ-UTR of 
PTEN and regulated CDDP resistance through the PI3K/Akt 
pathway with loss of PTEN [82]. As a tumor suppressor, 
miR-217 increases sensitivity to CDDP through inhibiting 
the PI3K/Akt signaling pathway in various cancers [83–85]. 
miR-217 enhanced sensitivity to CDDP via targeting KRAS 
and inhibiting the PI3K/Akt pathway in osteosarcoma [86]. 
In chondrosarcoma, reduced expression of miR-100 was 
associated with resistance to CDDP with activation of the 
Akt-mTOR pathway. Upregulated expression of miR-100 
sensitized chondrosarcoma cells to CDDP by inhibiting the 
Akt/mTOR pathway [87]. Loss of miR-497 induced drug 
resistance through targeting vascular endothelial growth 
factor A (VEGFA) in osteosarcoma. VEGFA is a member 
of the vascular endothelial growth factor (VEGF) family, 
which is a positive modulator of the PI3K/Akt pathway 
[88]. With depletive VEGFA, decreased miR-497 induced 
Akt activation, resulting in resistance to CDDP. In contrast, 
increased miR-497 inhibited cell survival and promoted 
sensitivity to CDDP with inhibition of the PI3K/Akt 
pathway [89]. 
The Wnt pathway is another cell-survival signaling 
pathway associated with drug resistance in sarcoma 
(Figure 3). miR profiles identified five discrete miRs 
(miR-92a, miR-99b, miR-132, miR-193a-5p and miR-
422a) in osteosarcoma, which have an impact on drug 
response through targeting the Wnt, TGFβ and MAP 
kinase pathways [90]. Overexpression of miR-33a also 
resulted in drug resistance in osteosarcoma, which was 
mediated by downregulation of TWIST [91]. TWIST is 
a negative regulator of CDDP resistance by suppressing 
the Wnt/β-catenin pathway in osteosarcoma [92]. Low 
expression of miR-34c contributed to drug resistance 
development in osteosarcoma [93]. miR-34c may target 
and inhibit Notch1 and LEF1 expression. Notch1 and 
LEF1 activated the Notch and the Wnt signaling pathway, 
promoting drug resistance in cancers, including in 
osteosarcoma [94–96]. Overexpression of miR-146b-5p 
promoted resistance to DOX, CDDP and methotrexate by 
promoting the Wnt/β-catenin pathway in osteosarcoma. 
Zinc and ring finger 3 (ZNRF3) is a direct target of miR-
146b-5p. Overexpression of miR-146b-5p downregulated 
ZNRF3 , thus activate Wnt/β-catenin pathway and induced 
drug resistance in osteosarcoma [97]. 
miRs are involved in CSC-related pathways in 
drug resistant sarcoma
The CSC hypothesis postulates that within a tumor, 
a minor subpopulation of cells possess the capacity to self-
renew and drive the heterogeneous lineages of cancer cells 
that account for the initiation, proliferation, recurrence, 
Figure 3: ncRNAs affect cell-survival pathways in drug resistant sarcoma. ncRNAs that regulate gene expression of important 
regulators in cell-survival pathways play a role in drug resistance in sarcoma. Red arrows indicate upregulation and green arrows indicate 
downregulation of miRs.
Oncotarget69094www.impactjournals.com/oncotarget
metastasis and therapeutic resistance in cancer [98]. CSCs 
may be involved in resistance to drugs and toxins through 
the expression of drug efflux transporters, activation of 
DNA repair, and evasion of apoptosis [99]. For example, 
CSCs express more anti-apoptotic proteins, including Bcl-
2, FLIP, IAP-1, IAP-2 and survivin than normal tumor 
cells to resist apoptosis in sarcoma [100]. Even though 
the molecular pathways modulating CSCs remain unclear, 
growing evidence highlights the roles of miRs in the 
regulation of drug resistance related to CSCs (Figure 4). 
Cluster of differentiation 44 (CD44) is a cell 
surface marker commonly used to identify and 
enrich CSCs [101]. Higher expression of this cell-
surface glycoprotein was associated with response to 
chemotherapy in osteosarcoma. miR-199a-3p is one of 
the most dramatically decreased miRs in osteosarcoma. 
Transfection of miR-199a-3p enhanced drug sensitivity, 
consistent with downregulation of CD44 in osteosarcoma. 
The 3ʹ-UTR of CD44 mRNA was the direct target of miR-
199a-3p [102]. In chemoresistant osteosarcoma cell lines, 
it was also observed that loss of miR-143 expression was 
accompanied by a high level of ALDH1+CD133+ cells. 
Forced miR-143 expression could reverse drug resistance 
in DOX-resistant osteosarcoma CSCs through activation 
of apoptosis [103]. CSCs in sarcoma can also induce 
evasion of apoptosis through p53 and Rb pathways to 
resist chemotherapeutic drugs [104]. The AB-OS cell 
line is a CSC cell line selected from human osteosarcoma 
MG63 cells. Overexpression of miR-29b-1 reduced the 
expression of stem cell markers (Oct3/4, Sox2, Nanog, 
CD133, and N-Myc) and anti-apoptotic markers (Bcl-2 
and IAP-2) in 3AB-OS CSCs, suggesting that miR-29b-1 
can inhibit stemness properties of 3AB-OS CSCs and 
sensitize 3AB-OS cells to chemotherapy drugs (DOX, 
CDDP and etoposide) in osteosarcoma [105]. On the 
contrary, upregulation of Let-7d reduced cell sensitivity to 
apoptosis and induced drug resistance in 3AB-OS cells, in 
combination with decreased caspase-3 and increased Bcl-2 
in osteosarcoma [65]. 
miRs impact autophagy in drug resistant 
sarcoma
Recent findings have suggested that dysregulated 
miRs are closely connected to autophagy modulation 
and cancer drug resistance (Figure 4). Autophagy is an 
Figure 4: miRs impact on CSCs and autophagy in drug resistant sarcoma. miRs that mediate gene expression of markers and 
regulators in CSCs and autophagy are implicated in drug resistance in sarcoma. Red arrows indicate upregulation of miRs and green arrows 
indicate downregulation.
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evolutionary conserved catabolic process involving in the 
degradation of proteins and organelles, cellular remodeling 
and survival, promoting the controlled degradation of 
cytoplasmic material both at steady state and during 
nutrient deprivation [106]. Tumor cell autophagy is 
activated during chemotherapy and contributes to 
chemotherapy resistance [107, 108]. Thus, inhibition 
of autophagy can re-sensitize resistant cancer cells and 
enhance cytotoxicity of chemotherapeutic agents [109, 
110]. Certain miRs have been revealed as potent inhibitors 
of drug resistance-related autophagy [111], indicating their 
potential role in cancer therapy [112, 113]. 
It has been shown that miR143 and miR-199-
5p suppress autophagy and reverse drug resistance in 
osteosarcoma (Figure 4). Upregulation of miR-143 was 
correlated with the sensitization of osteosarcoma cells 
to DOX, which is accompanied by downregulation of 
LC3-II and Bcl-2 [103]. CDDP treatment upregulated 
protein levels of LC3-II and Beclin1 in osteosarcoma 
cells, indicating that autophagy was activated. Restoration 
of miR-199a-5p inhibited CDDP-induced autophagy, 
indicating that miR-199a-5p promotes the cytotoxicity of 
CDDP in osteosarcoma through inhibition of autophagy 
[114]. Reduced miR-30a expression activated Beclin-1-
dependent autophagy, which influenced drug resistance 
in osteosarcoma cells to DOX. miR-30a directly binds to 
the 3ʹ-UTR of Beclin-1 gene, resulting in the suppression 
of Beclin-1 mediated autophagy. Elevated miR-30a 
expression promoted drug-induced apoptosis and inhibited 
autophagy activity in osteosarcoma [115, 116]. The 
expression of miR-22 was induced by chemotherapeutic 
drugs in osteosarcoma. High-mobility group box 1 
(HMGB1) is a direct target of miR-22, which could 
facilitate autophagy and promote drug resistance. miR-22 
blocked the HMGB1-mediated autophagy and reversed 
drug resistance in osteosarcoma [117, 118]. Autophagy-
characteristic acidic vesicular organelles (AVOs) are 
characteristic in autophagy. miR-101 could also reduce 
the DOX-induced AVOs and decrease autophagy-related 
proteins in osteosarcoma. Upregulated miR-101 enhanced 
chemosensitivity to DOX through inhibiting autophagy, 
thus reversing autophagy-mediated drug resistance in 
osteosarcoma [119]. 
ROLE OF LNCRNAS IN DRUG RESISTANT 
SARCOMA
LncRNAs are transcriptional polyadenylated RNAs 
that were first reported in 1990 [120]. They consist of 
exons and introns in structure, but lack valid ORFs 
[22]. LncRNAs regulate gene expression at epigenetic, 
transcriptional and post-transcriptional levels, through 
epigenetic regulation, splicing, imprinting, transcriptional 
regulation and subcellular transport [121–124]. They 
function in both cis, to act on the same chromosome, 
and trans, to affect different chromosomes [125, 126]. 
LncRNAs play a role in a number of biological processes, 
including chromatin modification, telomere biology 
and subcellular structural organization [127]. Current 
estimates of unique lncRNAs present in humans that range 
from 7000–23,000, with a growing cohort being validated 
as having a role in human disease processes, including 
in sarcoma [128, 129]. The misregulated lncRNAs can 
function as decoys, scaffolds, signals or guides for specific 
regulatory modules, resulting in a gene expression profile 
in favor of cancer drug resistance development (Table 3) 
[24, 130]. 
lncRNAs are associated with drug efflux and 
accumulation in drug resistant sarcoma
A human lncRNA-mRNA combined microarray 
revealed that 3,465 lncRNAs (1,761 up and 1,704 
down) were aberrantly expressed in DOX-resistant 
osteosarcoma cells. This lncRNA-mRNA co-expression 
network identified that upregulated expression of lncRNA 
EST00000563280 and downregulated expression of 
lncRNA NR-036444 could stimulate the expression 
of Pgp to transport the drugs out of the cell, leading to 
drug resistance to DOX in osteosarcoma (Figure 2) 
[131]. Pgp, also known as MDR1, is a 170 kDa cell 
membrane glycoprotein encoded by the ATP-binding 
cassette subfamily B member 1 (ABCB1) gene. ABCB1 
is a member of the ubiquitous ATP-binding cassette 
(ABC) superfamily, which contains 49 members divided 
into seven subclasses ranging from ABCA to ABCG 
[132]. As an ATP-dependent drug transporter, Pgp can 
extrude cytostatic agents against a drug concentration 
gradient at the expense of ATP hydrolysis. The action 
of Pgp triggers drug efflux and promotes resistance to 
drugs in cancer [133, 134]. In sarcoma, the acute induced 
expression of Pgp has been demonstrated as a function 
of time in response to in vivo exposure to chemotherapy 
[135, 136]. The novel lncRNA EST00000563280, termed 
osteosarcoma DOX-resistance related upregulated 
lncRNA (ODRUL), was the most upregulated lncRNA 
in DOX-resistant osteosarcoma cells. ODRUL plays a 
role in the emergence of resistance to DOX by inducing 
Pgp expression in osteosarcoma [137]. This indicates 
that lncRNAs may be a novel target for reversing drug 
resistance in sarcoma. 
lncRNAs regulate cell-survival pathways in drug 
resistant sarcoma
In addition to promoting cancer cell survival, 
activation of Wnt/β-catenin pathway can also induce drug 
resistance through affecting cell cycle in osteosarcoma 
(Figure 3) [138]. HOTTIP is another lncRNA upregulated 
in osteosarcoma. Overexpression of HOTTIP promoted 
cellular resistance to CDDP, accompanied by an activation 
of Wnt/β-catenin pathway. Decreasing HOTTIP induced 
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cell cycle arrest in G1 phase through inhibiting the 
Wnt/β-catenin pathway, thus reversing drug resistance in 
osteosarcoma [139]. 
The therapeutic potential of ncRNAs in drug 
resistant sarcoma
Identification of chemotherapy-resistant tumors at 
diagnosis is a first priority for treating sarcoma, where 
more individualized, effective, and less toxic treatments 
are highly desirable. ncRNA therapiesappear to be a novel 
field in which ncRNA activity is the major target of the 
intervention [140]. 
miRs are believed to be relatively safe and more 
effective in cancer treatment in early preclinical studies 
[141]. Recent evidence has confirmed that the selective 
modulation of miR activity could improve responses to 
chemotherapy. The rationale for developing miR therapies 
is based on the premise that aberrant expression of 
miRs play key roles in the development of resistance to 
chemotherapy and that correcting these miR deficiencies 
by either antagonizing or restoring miR function may 
provide a therapeutic benefit [142]. 
Overexpressions of some miRs are involved in 
drug-resistant human sarcoma. Inhibition of these miRs 
may increase chemoresponse to antitumor therapy. For 
example, miR-21 promotes drug resistance in sarcoma, 
and inhibition of miR-21 may function to reverse 
drug resistance in osteosarcoma cells [68]. Further 
understanding of miR-21-mediated signaling pathways 
will help to promote the clinical use of miR-21 in cancer 
treatment [143]. DOX is a widely used chemotherapy 
drug, but it has a narrow therapeutic window with toxic 
side-effects. The antitumor activity of DOX is achieved by 
induction of cell apoptosis through interacting with DNA 
[144]. The miR-488 is overexpressed in osteosarcoma 
and is induced by hypoxia through binding to the hypoxia 
response element. Overexpression of miR-488 decreased 
the sensitivity to DOX via direct targeting of the mediator 
of apoptosis Bim. Transfection of the miR-488 inhibitor 
resulted in an increase in apoptosis and enhanced the 
sensitivity of osteosarcoma cells to DOX treatment [145]. 
Overexpression of Let-7d also reduced osteosarcoma cell 
sensitivity to apoptosis induced by chemotherapy agents 
DOX, CDDP, etoposide and paclitaxel, concomitant with 
a decrease in caspase-3 and increase in BCL2 expression 
[65]. miR-184 also contributes to chemoresistance in 
osteosarcoma. The expression of miR-184 was upregulated 
in DOX-treated osteosarcoma cells. BCL2L1 served as 
the direct target gene of miR-184. Overexpression of 
miR-184 reduced DOX-induced cell apoptosis and led 
to poor response to drug therapy by targeting BCL2L1 
[146]. These observations indicate that miR-488, Let-
7d and miR-184 may serve as predictors of response to 
chemotherapy and as potential therapeutic targets for the 
treatment of drug resistant osteosarcoma. 
Some miRs are downregulated and related to drug 
resistance in sarcoma. Exogenous upregulation of these 
may promote sensitivity to chemotherapy. In Ewing’s 
sarcoma, miRNA expression was investigated in patients 
with different clinical outcomes. Microarray analysis 
identified a signature of miR-34a as a prognostic indicator 
for Ewing’s sarcoma [147]. Functional analysis indicated 
that miR-34a increased tumor sensitivity to the effects 
of DOX and vincristine in Ewing’s sarcoma cells, and 
that restoration of miR-34a activity may be useful to 
decrease malignancy. The result suggested a potential role 
of miR-34a in the treatment of sarcoma and may spare 
excessive long-term toxicity to Ewing’s sarcoma patients 
[69]. Chondrosarcoma is the second most common type 
of primary bone malignancy in the United States. The 
expression of miR-125b was decreased in both parental 
and DOX-resistant chondrosarcoma cells. Overexpression 
of miR-125 enhanced the sensitivity of both parental and 
DOX-resistant cells to DOX by inhibiting glycolysis 
through directly targeting the oncogene, ErbB2 [148]. 
CDDP is another widely used antitumor agent via effective 
DNA-damaging. However, chondrosarcoma is resistant to 
Table 3: Summary of lncRNAs involved in drug resistant sarcoma
lncRNAs Sarcomas Alteration Drugs Resistance 
mechanisms
Major 
targets
References
ENST00000563280 
(ODRUL)
Osteosarcoma ↑ Doxorubicin Evasion of 
apoptosis
ABCB1 [131, 137]
NR-036444 Osteosarcoma ↓ Doxorubicin Evasion of 
apoptosis
ABCB1 [131]
HOTTIP Osteosarcoma ↑ Cisplatin Activation of 
cell-survival 
pathways
Wnt/β-
catenin 
pathways
[139]
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conventional chemotherapies, including CDDP. Compared 
with the parental cells, miR-23b was significantly 
downregulated in CDDP-resistant cells. Src kinase is a 
direct target of miR-23b in chondrosarcoma cells. The 
chemo-sensitization effect induced by miR-23b-mediated 
suppression of the Src-Akt pathway suggests that miR-
23b could be a potential therapeutic target to reverse the 
acquirement of resistance to CDDP in chondrosarcoma 
[149]. These findings provide a novel therapy to 
overcoming chemoresistance in human chondrosarcoma 
cells. In neuroblastoma, miR-141 upregulation promoted 
chemosensitivity to CDDP, which was associated with the 
FUS gene, which may also help in the development of 
therapeutic strategies for the treatments of patients [150]. 
Moreover, lncRNAs have become a new frontier 
for drug development. The structural and functional 
novelty of lncRNAs offers promise as anticancer 
therapeutics that may avoid the emergence of drug 
resistance commonly seen with the currently used agents. 
For example, HOTAIR is a novel factor involved in 
drug resistance and metastasis in various types of solid 
tumors. Overexpression of HOTAIR was involved in 
drug resistance in primary sarcoma and decreased levels 
of HOTAIR were associated with good chemoresponse, 
suggesting that clinical application of HOTAIR may be a 
potential predictor of treatment efficacy [151]. 
Although there are still several obstacles to overcome 
before clinical testing of miR therapeutics, such as delivery 
and chemical modification of ncRNA modulators, it 
can be expected that ncRNAs and ncRNA-targeting 
oligonucleotides may become promising tools in the fight 
against drug resistant sarcoma in the near future [152]. 
CONCLUSIONS AND FUTURE 
PERSPECTIVES
The current rapid expansion of research on ncRNAs 
evidently shows that ncRNAs have many implications 
in drug resistant sarcoma. This review brings together 
information on the roles of ncRNAs in drug resistant 
sarcomas, including miRs and lncRNAs. Although 
the exact mechanisms of ncRNAs in drug resistance in 
sarcoma are still unclear, these studies highlight the 
increasing interest and development of knowledge of 
ncRNAs in drug resistant sarcoma.
Although recent findings present a positive trend 
in development, the research progress of ncRNAs in 
drug resistant sarcoma is still in its infancy. There is a 
tough route from discovering the function of ncRNAs 
to its clinical use. Despite extensive investigation 
and distinct progress in this field, there are still many 
challenges. Most of the current studies focus on the role 
of ncRNA in chemoresistance with a single agent, such 
as either DOX or CDDP. However, sarcoma patients 
commonly receive combined chemotherapy in the clinic. 
Thus, it is necessary to evaluate the role of ncRNA in 
the regulation of multidrug resistance. With regard to 
ncRNA-based therapeutic agent, the field will benefit 
from the development of RNA delivery technology and 
chemical modifications of ncRNAs. Novel RNA delivery 
technology may protect ncRNA from degradation and 
enable ncRNA to reach tumors efficiently and specifically. 
The chemical modifications of ncRNAs can enhance the 
stability of ncRNAs and reduce toxicity, minimizing side 
effects. Furthermore, discovery of more miR targets will 
be useful to better identify new and more effective drug 
targets [153]. 
A rising strategy to solve gene specificity 
limitations is the technology of genome editing by 
clustered regulatory interspaced short palindromic 
repeats-associated endonuclease 9 (CRISPR-Cas9), which 
is a rapid and efficient way to generate total or partial 
downregulation of specific genes, including ncRNAs, 
by the targeted interruption of the promoter and the 
chosen sequence through insertion of polyadenylation 
signals. Furthermore, CRISPR-Cas9 can be applied to 
achieve ncRNA overexpression from its endogenous 
locus by inserting a strong promoter upstream of 
the ncRNA sequence or by targeting transcriptional 
activator complexes to the promoter [154, 155]. In the 
future, after gaining insight into the ncRNAs involved 
in drug resistance mechanisms in sarcoma, ncRNA-
based approaches may provide important advances in 
overcoming drug resistance and improving chemotherapy 
responses of sarcoma patients.  
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